

# Data summary

	2002	2003	2004	2005	2006
<b>Access to medicines</b>					
Number of countries supplied with preferentially priced ARVs <sup>1</sup>	50	56	57	56	51
Number of preferentially priced <i>Combivir</i> and <i>Epivir</i> tablets shipped (millions) <sup>1</sup>	7.9	15.9	67.1	126.3	86.3
Number of generic ARVs supplied by GSK licencees (millions)	–	–	–	–	120
GSK <i>Combivir</i> not-for-profit price (\$ per day) <sup>2</sup>		1.7	0.65	0.65	0.65
Voluntary licences granted to generic manufacturers for GSK ARVs (cumulative total)			6	7	8
Value of products donated through GSK Patient Assistance Program in the US (£ millions)	112	125	203	255	200
<b>Research and development</b>					
Expenditure on R&D (£ billions)	2.9	2.8	2.9	3.1	3.5
GSK animal research facilities accredited by the Association for Assessment and Accreditation of Laboratory Animal Care	7	7	10	10	10 <sup>3</sup>
Number of trials published on the GSK Clinical Trial Register (cumulative total)	–	–	143	2,125	2,760 <sup>4</sup>
<b>Ethical conduct</b>					
Number of managers completing certification to the GSK Code of Conduct	700	9,000	9,600	>12,000	>12,000
Number of contacts through our ethics compliance channels <sup>5</sup>			2,580	3,644	5,363
<b>Employment</b>					
Women in management grades (%)	32	34	35	35	36
Ethnic diversity – minorities (US, %)	19	19.5	19.5	19.6	19.8
Ethnic diversity – ethnic minorities (UK, %)	–	–	15.5	16.8	18.3
Lost time injury and illness rate (cases per 100,000 hours worked)	0.34	0.30	0.30	0.30	0.33
<b>Environment</b>					
Number of contract manufacturers audited	16	28	35	41	36
Energy consumption (million gigajoules)	20	20	19	19	19
Water consumption (million cubic metres)	24	23	21	21	22
Ozone depletion potential from metered dose inhalers (tonnes CFC-11 equivalent) <sup>6</sup>	1,500	782	464	273	186
Ozone depletion potential from production (tonnes CFC-11 equivalent)	121	72	59	51	23
Ozone depletion potential from refrigeration and other ancillary uses (tonnes CFC-11 equivalent)	7	3	3	3	1
Volatile organic compound emissions (thousand tonnes) <sup>7</sup>	6	6	5	5	4
Global warming potential from energy sources (thousand tonnes CO <sub>2</sub> equivalent) <sup>7</sup>	1,734	1,750	1,666	1,693	1,666
Hazardous waste disposed (thousand tonnes) <sup>7</sup>	58	56	69	63	67
<b>Community investment</b>					
Total community investment expenditure (£ millions)	239	338	328	380	302
Value of humanitarian product donations, including albendazole (£ millions)	24	116	57	41	38
Number of albendazole tablets donated for prevention of lymphatic filariasis (millions)	66	94	67	136	155

1. Includes ARVs sold at not-for-profit and discounted prices. We are unable to collect data for the number of patients treated.

2. Includes delivery costs. The Médecins Sans Frontières pricing report lists the average cost of generic equivalents.

3. This covers 91% of animals used in GSK facilities. In 2005 we had 14 animal research laboratories. In 2006 we closed a laboratory in Japan, acquired laboratories in Croatia and Canada, and established contracts to use laboratories in Singapore and the US, making a current total of 17 GSK laboratories where we use animals.

4. 98% of trials completed since the merger which created GSK.

5. Includes contacts with line managers, compliance officers, our confidential Integrity Helplines or offsite post office box (in the US).

6. 2002 to 2004 data do not include inhalers made in Asia.

7. We have changed the way we calculate these data and the previous years' data reflect this change. See full environmental report for details.

## Trademarks

Brand names appearing in italics throughout this publication are trademarks either owned by and/or licensed to GSK or associated companies.